May 7, 2026 11:58 AM
Moderna’s mRNA flu vaccine outperforms standard shot in late-stage trial
Moderna's mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on Wednesday. The vaccine is currently under review by the U.S. Food and Drug Administration after the agency rejected the company's initial application. A decision is expected by August 5. If approved, Moderna's shot would be the first seasonal flu shot in the United States made with mRNA technology, a faster...